Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 8Gastrointestinal 5Genitourinary 2Breast 2Thoracic 1Sarcoma 1Head & Neck 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 25Colorectal Neoplasms 21Lung Neoplasms 12Neoplasms 7Pancreatic Neoplasms 6Ovarian Neoplasms 6Head and Neck Neoplasms 6Colonic Neoplasms 6Stomach Neoplasms 5Esophageal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Small Cell Lung Carcinoma 4Rectal Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Peritoneal Neoplasms 3Mesothelioma 3Melanoma 3Carcinoma, Pancreatic Ductal 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Kidney Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Renal Cell 2Biliary Tract Neoplasms 2Vipoma 1Uterine Cervical Neoplasms 1Tracheal Neoplasms 1Spinocerebellar Degenerations 1

Interventions

pembrolizumab 30Carboplatin 13Trastuzumab 8Paclitaxel 7Nivolumab 7Cisplatin 6Ipilimumab 5Cetuximab 5Bevacizumab 5Taxes 4Pemetrexed 4Specimen Handling 3Irinotecan 3Docetaxel 3Cyclophosphamide 3Biopsy 3tisotumab vedotin 2temsirolimus 2spartalizumab 2sargramostim 2pertuzumab 2lenvatinib 2fludarabine 2epacadostat 2enzalutamide 2aldesleukin 2X-Rays 2Ritonavir 2Psychiatric Rehabilitation 2Oxaliplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Fluorouracil × Thoracic × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡